Dementia constitutes a major burden on society, both in monetary costs and the suffering of patients and their relatives. It comprises a number of diseases including Alzheimer’s disease (AD) and vascular dementia (VaD). In recent...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
TEC2012-34306
DIAGNOSTICO MEDIANTE MODELOS ESTADISTICOS E INTELIGENTES (DI...
81K€
Cerrado
TEC2008-02113
NUEVAS TECNICAS DE RECONSTRUCCION, PROCESADO, CLASIFICACION...
66K€
Cerrado
FLUBIODEM
Fluid Biomarkers for Neurodegenerative Dementias
2M€
Cerrado
TEC2008-02113
NUEVAS TECNICAS DE RECONSTRUCCION, PROCESADO, CLASIFICACION...
66K€
Cerrado
VASCAMY
Vascular and Aymloid Predictors of Neurodegeneration and Cog...
100K€
Cerrado
TEC2009-14587-C03-02
BIOMARCADORES DE NEUROIMAGEN EN ENFERMEDADES NEURODEGENERATI...
70K€
Cerrado
Información proyecto DEMO
Duración del proyecto: 48 meses
Fecha Inicio: 2016-08-01
Fecha Fin: 2020-08-31
Líder del proyecto
BIOMEDIQ AS
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
853K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Dementia constitutes a major burden on society, both in monetary costs and the suffering of patients and their relatives. It comprises a number of diseases including Alzheimer’s disease (AD) and vascular dementia (VaD). In recent years, imaging biomarkers have been developed including measures of brain morphology (MRI T1), vascular pathologies (MRI T2*/FLAIR), white matter abnormalities (MRI DWI), perfusion (MRI ASL), glucose turnover (PET FDG), and accumulation of pathological proteins (PET PIB/AV45). Quantitative measures using these biomarkers in large cohort studies have the potential to model the pathological process of the disease. This proposal would create an innovative training network, in which early stage researchers will develop new computational imaging biomarkers, under the supervision of experienced researchers, for the purpose of modeling dementia etiology. One researcher will investigate quantification of vascular pathologies, another will develop quantitative measures of white matter abnormalities from structural MRI, and the final researcher will construct a quantitative model of disease etiology using a maximum-likelihood framework. The early stage researchers will be enrolled as PhD students at University College London (UCL) under the EPSRC Centre for Doctoral Training in Medical Imaging (CDT), which is based in Centre for Medical Image Computing (CMIC), with the Dementia Research Centre (DRC) being one of the main clinical collaborators for CDT studentships. However, they will spend the majority of time at the research facilities of Biomediq A/S, Copenhagen Denmark, where they will be exposed to industry and work under professional guidance.